Skip to main content
editorial
. 2006 Nov 7;12(41):6693–6698. doi: 10.3748/wjg.v12.i41.6693

Table 2.

Comparative results according to changing patterns of HBeAg levels during LAM therapy

Response Non- response or reakthrough Odds atio 95%CI) Sensitivity Specificity PPV1 NPV2
At 6 mo 4. 8 (2.2-13.5) 83 49.7 34.4 90.2
D3 44 84
N4 9 83
D-C5   0 0
At 9 mo 11.0 (3.8-32.0) 92.5 47.9 36 95.2
D 49 87
N 4 67
D-C 0 13
At 12 mo 10.5 (3.6-30.5) 92.5 46.7 35.5 95.1
D 49 89
N 2 60
D-C 2 18
1

Positive predictive value. The proportion of patients achieving HBeAg seroconversion among those with decrescendo pattern of HBeAg levels at each time after initiation of therapy;

2

Negative predictive value. The proportion of patients without HBeAg seroconversion among those with the decrescendo-crescendo and no change or fluctuating patterns during treatment;

3

Decrescendo pattern. Continuously decreasing HBeAg levels by more than 90% of pretreatment values;

4

No change or fluctuating pattern. No change or fluctuation of HBeAg levels during treatment;

5

Decrescendo-crescendo pattern. A continuous decrease of HBeAg levels by more than 90% of pretreatment values, and then progressively increasing.